-- Scott Roberts
WEDNESDAY, Nov. 2 (HealthDay News) -- MelaFind -- a device that
creates digital images of suspicious skin growths and compares them
to a database of thousands of scans to analyze for signs of
melanoma skin cancer -- has been approved by the U.S. Food and Drug
The non-invasive diagnostic can help doctors decide whether to
biopsy skin growths in their early stages, when skin cancer is
nearly 100 percent curable, device maker Mela Sciences said in a
Melanoma, if not caught in its earliest stages, is the deadliest
form of skin cancer. It accounts for about 75 percent of skin
cancer deaths, the company said.
While the new technology can recommend to doctors whether to
perform a biopsy, it is
not intended to confirm a clinical diagnosis of melanoma,
The company is based in Irvington, N.Y.
The U.S. National Cancer Institute has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.